DexCom, Inc. (DXCM) reported third-quarter 2026 revenue of $1.34 billion, up 11.2% from a year earlier, as the diabetes technology company continued to expand sales and improve profitability.
Key results included:
Cash generation was softer, with cash from operating activities falling to $325.6 million. Cash and cash equivalents ended the quarter at $961.4 million, while total liabilities declined to $3.70 billion.
Shares rose 2.19% after the market close following the release.
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
DexCom, Inc. Insider Trading Activity
DexCom, Inc. insiders have traded $DXCM stock on the open market 26 times in the past 6 months. Of those trades, 0 have been purchases and 26 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by insiders over the last 6 months:
- KEVIN R SAYER (Executive Chair) has made 0 purchases and 6 sales selling 107,027 shares for an estimated $8,303,321.
- MICHAEL JON BROWN (EVP Chief Legal Compliance Off) has made 0 purchases and 6 sales selling 10,200 shares for an estimated $801,261.
- JON COLEMAN (EVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 9,823 shares for an estimated $722,628.
- NICHOLAS AUGUSTINOS has made 0 purchases and 2 sales selling 8,089 shares for an estimated $679,768.
- SADIE STERN (EVP Chief People & Culture Off) has made 0 purchases and 3 sales selling 7,695 shares for an estimated $649,304.
- MARK G FOLETTA has made 0 purchases and 4 sales selling 8,000 shares for an estimated $627,179.
- JEREME M SYLVAIN (EVP, Chief Financal Officer) sold 3,638 shares for an estimated $302,936
- BRIDGETTE P HELLER has made 0 purchases and 2 sales selling 2,024 shares for an estimated $150,079.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
DexCom, Inc. Hedge Fund Activity
We have seen 532 institutional investors add shares of DexCom, Inc. stock to their portfolio, and 452 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INVESCO LTD. added 9,693,273 shares (+173.3%) to their portfolio in Q2 2026, for an estimated $652,841,936
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 4,328,170 shares (+170.1%) to their portfolio in Q2 2026, for an estimated $291,502,249
- D. E. SHAW & CO., INC. removed 3,932,889 shares (-99.9%) from their portfolio in Q2 2026, for an estimated $264,880,074
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 3,439,164 shares (+inf%) to their portfolio in Q2 2026, for an estimated $231,627,695
- JPMORGAN CHASE & CO added 3,325,095 shares (+inf%) to their portfolio in Q2 2026, for an estimated $223,945,148
- CASTLE HOOK PARTNERS LP added 3,068,495 shares (+382.7%) to their portfolio in Q2 2026, for an estimated $206,663,138
- LOS ANGELES CAPITAL MANAGEMENT LLC removed 1,805,701 shares (-99.7%) from their portfolio in Q2 2026, for an estimated $121,613,962
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
DexCom, Inc. Congressional Stock Trading
Members of Congress have traded $DXCM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $DXCM stock by members of Congress over the last 6 months:
- SENATOR TINA SMITH sold up to $250,000 on 05/07.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.
DexCom, Inc. Price Targets
Multiple analysts have issued price targets for $DXCM recently. We have seen 9 analysts offer price targets for $DXCM in the last 6 months, with a median target of $85.0.
Here are some recent targets:
- Kieran Ryan from Deutsche Bank set a target price of $86.0 on 06/23/2026
- Matt O'Brien from Piper Sandler set a target price of $88.0 on 06/15/2026
- Joshua Jennings from TD Cowen set a target price of $95.0 on 06/10/2026
- Anthony Petrone from Mizuho set a target price of $85.0 on 06/09/2026
- Jonathan Block from Stifel set a target price of $90.0 on 06/05/2026
- Joanne Wuensch from Citigroup set a target price of $84.0 on 05/28/2026
- Matt Miksic from Barclays set a target price of $64.0 on 05/18/2026
